Combination immune therapy in melanoma: a tale of two therapies

Comparative trials examining the outcomes of the two standard combination immune therapies, ipilimumab and nivolumab or relatlimab and nivolumab, in frontline therapy for patients with metastatic melanoma are not yet available. This article discusses the known and unknowns in choosing between ipilimumab and nivolumab or relatlimab and nivolumab and provides an outline of discussion between patients and physicians.

Please enter your email to access content Read now